PrioCam Ltd. (PrioCam) is a dynamic biotechnology company providing exciting and unique technology which enables production of novel antibodies capable of binding to prion proteins. PrioCam’s exciting platform of technology additionally assists these novel antibodies to cross the blood-brain barrier (BBB). The BBB remains a bottleneck in brain drug development and is the single most important factor limiting the growth of drug development that specifically targets brain disorders. PrioCam Ltd. is committed to overcoming this bottleneck.
www.priocam.co.uk